VANCOUVER, British Columbia,
April 30, 2015 /PRNewswire/
-- InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB:
IMLFF), a clinical stage biopharmaceutical company that specializes
in developing safer, more effective cannabis-based therapies, today
announced it is now eligible for book-entry delivery and depository
services of The Depository Trust Company (the "DTC") to facilitate
electronic settlement of transfers of its common shares in
the United States. This electronic
method of clearing securities speeds up the receipt of stock and
cash, and thus accelerates the settlement process for
investors.
"With our shares now trading electronically, a standard in
today's financial markets, the process of trading and exchanging
our common stock by U.S investors is greatly simplified. Investors
can instantly benefit from greater liquidity and faster execution
speeds, lower costs and enhanced convenience," stated Craig Schneider, InMed President and CEO.
The DTC is a subsidiary of the Depository Trust & Clearing
Corporation (DTCC), and manages the electronic clearing and
settlement of publicly traded companies. Securities that are
eligible to be electronically cleared and settled through the DTC
are considered "DTC eligible." The eligibility process
enhances capital market efficiencies and reduces costs to the
industry by enabling eligible securities to be distributed, settled
and serviced through DTC's automated processes.
About InMed
InMed is a clinical stage
biopharmaceutical company that specializes in developing novel
therapies through the research and development into the extensive
pharmacology of cannabinoids coupled with innovative drug delivery
systems. InMed's proprietary platform technology, product pipeline
and accelerated development pathway are the fundamental value
drivers of the company.
For more information, visit www.inmedpharma.com
ON BEHALF OF THE BOARD
InMed Pharmaceuticals Inc.
Craig
Schneider
President and Chief Executive
Officer
T: 604.669.7207
F: 604.683.2506
E: info@inmedpharma.com
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
(Investors)
jdrumm@tiberend.com
212-375-2664
Amy Wheeler (Media)
awheeler@tiberend.com
646-362-5750
Forward Looking Statements
This news release may contain forward-looking statements and
information based on current expectations. These statements
should not be read as guarantees of future performance or results.
Such statements involve known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by such
statements. Although such statements are based on management's
reasonable assumptions, there can be no assurance that such
assumptions will prove to be correct. We assume no
responsibility to update or revise them to reflect new events or
circumstances.
Additionally, there are known and unknown risk factors which
could cause InMed Pharmaceuticals actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed Pharmaceuticals
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
These risks and uncertainties include, among others, the
possibility that clinical trials will not be successful, or be
completed, or confirm earlier clinical trial results, risks
associated with obtaining funding from third parties, risks related
to the timing and costs of clinical trials and the receipt of
regulatory approvals
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/inmed-pharmaceuticals-qualifies-for-electronic-trading-in-the-us-300075161.html
SOURCE InMed Pharmaceuticals, Inc.